Remoxy Review Shows How Opana ER Experience Changed US FDA Thinking On New Opioid Formulations

 
• By Sue Sutter

Pain Therapeutics CEO Barbier says comparing Remoxy to Endo's withdrawn Opana ER 'borders on slanderous' and asserts that after three complete response letters, FDA is once again moving goalposts for approval.

American Football Goal Posts
What the US FDA sees as new and emerging methods of manipulation to defeat abuse-deterrent formulations, Pain Therapeutics sees as moving the goalposts for regulatory approval.

More from US FDA Performance Tracker

More from Regulatory Trackers